Boundless Bio (BOLD) vs Kalaris Therapeutics (KLRS)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Boundless Bio (BOLD) has outperformed Kalaris Therapeutics (KLRS) over the past year, gaining 97.7% versus a loss of 62.1%. Boundless Bio is the larger company by market cap ($57.6 million vs $56.2 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | BOLD | KLRS |
|---|---|---|
| Share price | $2.53 | $2.36 |
| Market cap | $57.55M | $56.18M |
| 1-day change | -1.94% | -5.60% |
| YTD return | +110.83% | -70.38% |
| 1-year return | +97.66% | -62.06% |
| 5-year return | — | -99.51% |
| EPS (TTM) | $-2.84 | $-1.95 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $3.16 | $11.88 |
| 52-week low | $0.961 | $2.35 |
| Distance from 52-week high | -20.04% | -80.13% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | +58.10% | +692.80% |
| Average volume | 182.04K | 252.88K |
| Shares outstanding | 22.75M | 23.80M |
| Employees | 28 | 20 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- BOLD has outperformed KLRS by 159.7 percentage points over the past year.
About Boundless Bio
BOLD stock →Boundless Bio, Inc., a clinical-stage oncology company, develops interrogating extrachromosomal DNA (ecDNA) directed therapies for treating patients with oncogene amplified cancers. Its lead product candidate is BBI-940, an ecDNA-directed therapeutic candidate (ecDTx) that is in Phase 1/2 clinical trial in patients with estrogen receptor positive and human epidermal growth factor receptor 2 negative breast cancer, as well as patients with triple-negative breast cancer luminal androgen receptor subtype.
Health Care · Biotechnology: Pharmaceutical Preparations · 28 employees
About Kalaris Therapeutics
KLRS stock →Kalaris Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development and commercialization of treatments for prevalent retinal diseases. It develops TH103, a clinical-stage anti-vascular endothelial growth factor (VEGF) drug for the treatment of neovascular age-related macular degeneration (nAMD), which is in Phase 1b/2, as well as for the treatment of other exudative and neovascular retinal diseases.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 20 employees
BOLD vs KLRS FAQ
Which is bigger, Boundless Bio or Kalaris Therapeutics?
Boundless Bio (BOLD) is larger, with a market capitalization of $57.55M compared with $56.18M for Kalaris Therapeutics (KLRS).
Which stock has performed better over the past year, BOLD or KLRS?
BOLD returned +97.66% over the past 12 months, compared with -62.06% for KLRS (price return, excluding dividends). Past performance does not predict future results.
Are Boundless Bio and Kalaris Therapeutics in the same industry?
Both are in the Health Care sector, but in different industries: Biotechnology: Pharmaceutical Preparations for Boundless Bio and Biotechnology: Biological Products (No Diagnostic Substances) for Kalaris Therapeutics.